Argenx Se (ARGX) Short term Debt (2015 - 2018)

Argenx Se's (ARGX) quarterly Short term Debt came in at $25.8 million in Q2 2018, up 42.9% on a QoQ basis from $18.0 million in Q4 2017.

Argenx Se (ARGX) Short term Debt (2015 - 2018) Analysis & Trends

Argenx Se (ARGX) has 4 years of Short term Debt data on file, last reported at $25.8 million in Q2 2018.

Quarterly Short term Debt changed N/A year-over-year to $25.8 million in Q2 2018, while the trailing twelve-month figure through Jun 2018 was $25.8 million (changed N/A YoY) and the FY2017 annual result came in at $18.0 million, up 36.94% from the prior year.
Short term Debt climbed to $25.8 million in Q2 2018, from $18.0 million in the prior quarter.
In the past five years, Short term Debt ranged from a high of $25.8 million in Q2 2018 to a low of $5.0 million in Q4 2015.
A 4-year average of $15.5 million and a median of $15.6 million in 2016 frame the typical range for Short term Debt.
Annual changes were most pronounced in 2016 — Short term Debt soared 164.36% — and 2017, when it soared 36.94%.
Tracing ARGX's Short term Debt over 4 years: stood at $5.0 million in 2015, then soared by 164.36% to $13.2 million in 2016, then jumped by 36.94% to $18.0 million in 2017, then surged by 42.9% to $25.8 million in 2018.
The last three Short term Debt figures came in at $25.8 million (Q2 2018), $18.0 million (Q4 2017), and $13.2 million (Q4 2016), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Roivant Sciences	26.16 Bn	26.85 Bn	1.16 Mn

Download Data